Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Celgene (CELG) Is A Top-Growth Biotech Stock; High P/E Multiple And Global Expansion Of Its Myeloma Franchise And REVLIMID Makes It A Top Stock Pick
Celgene (CELG) Is A Top-Growth Biotech Stock; High P/E Multiple And Global Expansion Of Its Myeloma Franchise And REVLIMID Makes It A Top Stock Pick
Celgene (CELG) Is A Top-Growth Biotech Stock; High P/E Multiple And Global Expansion Of Its Myeloma Franchise And REVLIMID Makes It A Top Stock Pick
Submitted by
admin
on April 10, 2010 - 11:39am
Source:
Yahoo/Wall St. Transcript
News Tags:
Celgene
Revlimid
Multiple Myeloma
Headline:
Celgene (CELG) Is A Top-Growth Biotech Stock; High P/E Multiple And Global Expansion Of Its Myeloma Franchise And REVLIMID Makes It A Top Stock Pick
Do Not Allow Advertisers to Use My Personal information
